Search PubMed⌕ Search

Biomedical subjects

P E Pool

Publications and source records attributed to P E Pool.

At least 37 records · Page 2Linked to original sources

Metabolic changes with antihypertensive therapy of the salt-sensitive patient.

Recent evidence suggests that metabolic changes that occur with antihypertensive agents may influence cardiovascular risk. Diuretic therapy is particularly appropriate for the salt-sensitive hypertensive patient. However, diuretic-induced electrolyte abnormalities may lead to ventricular arrhythmias, even in patients with uncomplicated essential hypertension. Antihypertensive drugs may change circulating lipoprotein levels, which may influence the development of atherosclerosis. Therefore, serum cholesterol and triglyceride levels should be monitored when antihypertensive drugs are administered that can cause hyperlipidemia. Weight reduction and diet therapy should be used because these may have a greater effect on reducing hyperlipidemia, though choice of antihypertensive agents is important. In addition, glucose tolerance may worsen with thiazide therapy, perhaps because newer evidence suggests that insulin resistance is common in essential hypertension. This glucose intolerance may be corrected with potassium repletion or substitution of bumetanide for thiazide. The calcium antagonists may be substituted for diuretic therapy, or other classes of antihypertensive drugs may be used with a reduced dose of diuretic drug if these metabolic changes persist. Thus, attention to metabolic changes may be as important as blood pressure reduction in treatment of the salt-sensitive hypertensive patient.

Antihypertensive Agents↗

Efficacy of a new calcium antagonist PN 200-110 (isradipine) in angina pectoris.

Angina pectoris is one of the major syndromes against which to test the therapeutic effectiveness of any new calcium antagonist. An interim analysis of the efficacy and safety of a new dihydropyridine calcium antagonist (PN 200-110 [isradipine]) in patients with confirmed coronary artery disease is reported. The study was carried out in 3 centers; 50 patients of an anticipated 96 have completed the double-blind comparative phases in 3 separate studies. Preliminary results from the placebo-controlled study indicate that PN 200-110 was significantly more effective than placebo in reducing the anginal attack rate and glyceryl trinitrate consumption in the 15 patients so far enrolled. Dose-response comparisons against nifedipine in 21 patients and against isosorbide dinitrate in 14 patients demonstrate that PN 200-110 has a similar antianginal efficacy profile to both drugs. No significant change in any of the monitored safety factors was noted in any of the patients taking PN 200-110. The side-effects profile compared favorably with that of nifedipine. These interim results suggest that PN 200-110 will prove to be an effective and safe drug for the treatment of angina pectoris.

Angina Pectoris↗

Treatment of supraventricular arrhythmias with encainide.

Encainide has been used to treat 230 patients with supraventricular arrhythmias, including patients with reentry supraventricular tachycardia of the atrioventricular reentry (Wolff-Parkinson-White syndrome) and the atrioventricular nodal reentry types associated with atrial fibrillation, paroxysmal supraventricular tachycardia or both, as well as incessant supraventricular tachycardia. The available data are summarized in this review. The short- and long-term response to encainide for preventing recurrence or lessening symptoms was excellent in most cases. There was little arrhythmia aggravation, and side effects, which were mostly central nervous system and visual in nature, did not cause discontinuation of the drug. Anterograde accessory pathway block was clearly an important effect. Whether retrograde block or refractoriness in the accessory pathway is the most important mechanism remains to be resolved. Pediatric patients with tachycardia-related cardiomyopathy responded well to encainide. Oral encainide's absence of effect on blood pressure or myocardial contractility is an added benefit.

Anilides↗

Diltiazem as monotherapy for systemic hypertension: a multicenter, randomized, placebo-controlled trial.

A multicenter, randomized, placebo-controlled, parallel group study of diltiazem in essential hypertension was carried out in 77 patients (40 diltiazem, 37 placebo) with stable supine diastolic blood pressure (BP) between 95 and 110 mm Hg. Patients were withdrawn from previous antihypertensive therapy for at least 4 weeks, titrated to the optimal dose, and followed for a total of 12 weeks during therapy. A diltiazem dose of 360 mg/day was required in 85% of the patients. Average BP in all positions was significantly (p less than 0.0001) reduced by diltiazem compared with placebo. With diltiazem, average supine BP fell from 156/100 mm Hg at baseline to 141/87 at end titration and 145/90 mm Hg at week 12, whereas average standing BP fell from 152/101 mm Hg to 136/90 and 143/91 mm Hg, respectively, at those times. There was no significant change in heart rate at week 12. Diltiazem tended to be more effective in older patients, but caused no increase in orthostatic BP drop. There were no statistically significant changes in BP in the placebo group. Two patients receiving placebo and 1 patient receiving diltiazem discontinued therapy as a result of adverse effects, and overall, side effects were only slightly more common with diltiazem treatment. Thus, diltiazem was effective and well tolerated single therapy for mild to moderate systemic hypertension and appears to compare favorably to most agents being used.

Age Factors↗

Comparative study of encainide and quinidine in the treatment of ventricular arrhythmias.

The antiarrhythmic efficacy and safety of oral encainide hydrochloride and quinidine sulfate were compared in a nine center double-blind crossover study in 187 outpatients with benign or potentially lethal ventricular arrhythmias. Patients with at least 30 premature ventricular complexes/h were randomized to receive either encainide, 25 mg four times/day, or quinidine, 200 mg four times/day, for 2 weeks. These doses were continued for another 2 weeks if a 75% or greater reduction in premature ventricular complexes was observed. If this reduction was not seen, encainide was increased to 50 mg four times/day or quinidine to 400 mg four times/day for an additional 2 weeks. Both drugs produced a statistically significant reduction in premature ventricular complex frequency compared with baseline values. Encainide produced a statistically significant greater mean reduction in total premature ventricular complexes than did quinidine during the initial dose phase and after dose adjustment. More patients required dose increases of quinidine (60%) than of encainide (51%). Early discontinuation of treatment resulting in advancement to the next study period occurred in 12 patients taking encainide and 38 patients taking quinidine (p less than 0.05). PR and QRS intervals increased significantly during encainide treatment, as did QTc and JT intervals during quinidine treatment. No adverse reactions resulted from these electrocardiographic changes. Adverse reactions were more common with quinidine than with encainide.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗

Effects of diltiazem on serum lipids, exercise performance and blood pressure: randomized, double-blind, placebo-controlled evaluation for systemic hypertension.

Treatment of hypertension with diuretics, beta blockers and alpha blockers may be associated with adverse effects on exercise performance, serum lipids and blood chemistries, as well as with orthostatic effects and fluid retention. A randomized, double-blind, placebo-controlled trial of a sustained-release preparation of diltiazem as sole therapy for moderate essential hypertension was conducted. Diltiazem was administered 2 times a day (360 mg/day) to 16 patients and placebo to 14 patients in a 12-week study. Average supine blood pressure with diltiazem therapy fell from 161/100 to 144/87 mm Hg without fluid retention or orthostatic effects. In an open-label study, patients from the placebo and diltiazem groups continued with diltiazem therapy. At an average of over 8 months, supine blood pressure on diltiazem was 147/88 mm Hg, and after withdrawal to single-blind placebo, average supine blood pressure increased to 173/104 mm Hg. All changes were significant compared with baseline and placebo (p less than 0.01). On diltiazem therapy, maximal treadmill exercise was increased by an average of 55 seconds (p less than 0.01), whereas heart rate, blood pressure and double product (heart rate X blood pressure) were reduced at submaximal exercise, and heart rate and double product were reduced at maximal exercise. No changes in serum glucose, potassium or uric acid were found. No adverse effects on serum lipids occurred. Diltiazem treatment was associated with an increase in high-density lipoprotein cholesterol (52 to 60 mg/dl, p less than 0.006) and a decrease in total cholesterol:high-density lipoprotein cholesterol ratio (4.7 to 4.2, p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Benzazepines↗

Long-term monotherapy of angina pectoris with diltiazem.

Eighteen patients with exertional angina were treated with diltiazem (360 mg/day). Serial exercise testing was performed and the results were compared to evaluations when patients were receiving placebo at the initiation and termination of the study. Serial exercise tests indicated significant improvement in duration of exercise (+18%, p less than 0.001), time to 1 mm ST depression (+32%, p less than 0.005), and time to angina (+46%, p less than 0.001) when patients were receiving diltiazem. During diltiazem treatment, there was a significant reduction in myocardial oxygen demand as indicated by the change in submaximal pressure rate product. This may contribute to the beneficial effect of diltiazem in patients with exertional angina. The reduction in pressure rate product was due primarily to a change in heart rate. This study provides evidence that diltiazem is an effective long-term monotherapy for angina; no evidence of drug tachyphylaxis was apparent after a total of 16 months treatment with diltiazem.

Aged↗

Clinical hemodynamic profile of trimazosin in hypertension.

This report describes the clinical hemodynamic response of hypertensive patients to trimazosin. Data were drawn from six different clinical trials involving a total of 171 study patients. Some of the patients were represented in more than one study. These studies range from single-dose experiences, through long-term administration for periods greater than 1 year, to hour-by-hour observation of effects following single doses. These data demonstrate that (1) trimazosin is an effective antihypertensive agent for controlling both systolic and diastolic pressure, (2) its optimum daily dose in monotherapy in this study was at least 600 mg/day, (3) its effects persist without loss of efficacy for more than 1 year, (4) its effects involve a decrease in peripheral vascular resistance without significant cardiac effects, (5) effects on heart rate are small and are seen only mildly in the presence of diuretics in the standing position (being due to the diuretics), (6) reduction of blood pressure during exercise appears to be less than that at rest, and (7) its side effects appear to be minor and are, for the most part, a reflection of its hemodynamic effects.

Adult↗

Trimazosin for the treatment of hypertensive patients failing to respond to thiazides.

In a double-blind study of two populations-one in Birmingham, Alabama, the other in Encinitas, California-a total of 32 hypertensive patients whose blood pressure was not controlled by thiazides alone were evaluated for their response to trimazosin. Patients showing a persistent diastolic blood pressure above 90 mm Hg while receiving 2 mg polythiazide once a day (at Birmingham) or 50 mg hydrochlorothiazide twice a day (at Encinitas) during a baseline 4-week period were randomly assigned to trimazosin and placebo groups. At both clinics, patients had a greater blood pressure response to trimazosin than to placebo in both supine and standing positions. When the data were pooled, the change in supine blood pressure (systolic/diastolic) between the average baseline values and the double-blind period was more than twofold greater for the trimazosin group, a decrease of 12.3/10.9 mm Hg (p less than 0.001). A lesser decrease of 5.4/5.4 mm Hg occurred in the placebo group, significant only for the diastolic pressure (p less than 0.01). Comparative differences between the trimazosin and the placebo groups were more marked for the standing blood pressures, -11.7/-10.0 mm Hg (p less than 0.0001) vs no significant change, +2.3/-2.8 mm Hg, respectively. Little change occurred in the patients' heart rates in either position in either treatment group. Adverse reactions were not clinically important and occurred in about half of the patients in the trimazosin and placebo groups. Therapy was not discontinued in either group because of adverse reactions.(ABSTRACT TRUNCATED AT 250 WORDS)

Antihypertensive Agents↗

Efficacy of diltiazem in angina on effort: a multicenter trial.

During a multicenter study 57 patients with exercise-induced angina were evaluated with serial exercise testing to assess the efficacy of diltiazem, a calcium slow channel blocking agent, compared with a placebo. The study consisted of a 1 week single-blind placebo stabilization period followed by a double-blind triple crossover between diltiazem and placebo. Three dose levels were tested (120, 180 and 240 mg/day) in each patient. For the three time-related variables there was a significant dose-related response, with 240 mg/day being the most effective. The increases, over the washout placebo stabilization values, of the time-related variables for the 240 mg/day week compared with the corresponding placebo week were total duration of exercise 1.87 versus 1.05 minutes (p less than 0.002), time to onset of angina 1.81 versus 1.17 minutes (p less than 0.01) and time to appearance of 1 mm S-T segment depression 1.81 versus 1.01 minutes (p less than 0.002). Analysis of exercise variables indicated a significant reduction in heart rate, diastolic blood pressure, and pressure-rate product at submaximal exercise after administration of diltiazem. Diastolic blood pressure was significantly reduced at maximal exercise. Heart rate and pressure-rate product were unchanged at rest during submaximal or maximal exercise. Submaximal and maximal exercise S-T depression was not significantly altered by diltiazem. The reduction in pressure-rate product at submaximal exercise was a possible mechanism for the drug's beneficial effect in enhancing the three time-related variables.

Adult↗

Long-term efficacy of diltiazem in chronic stable angina associated with atherosclerosis: effect on treadmill exercise.

Short-term efficacy of diltiazem in prolonging exercise end points in patients with chronic stable atherosclerosis-associated angina has been demonstrated. The safety and efficacy of diltiazem were examined in a placebo-controlled exercise study over 4 months (eight patients) and subsequently at 12 to 16 months (six patients). Three end points were evaluated: (1) time to onset of angina or fatigue if angina were eliminated; (2) time to 1 mm S-T segment depression or termination of exercise if S-T depression were eliminated; and (3) time to termination of exercise (2+ angina or fatigue). All end points were significantly prolonged over the medium-term 4 month study and decreased again significantly with return to placebo. Maximal effect occurred at 3 months with the first end point increasing from a mean +/- standard error of the mean of 7.2 +/- 1.2 to 10.2 +/- 0.9 minutes (p less than 0.01), the second end point from 8.0 +/- 0.9 to 10.3 +/- 1.0 minutes (p less than 0.01), and the third end point from 9.6 +/- 1.3 to 11.9 +/- 0.8 minutes (p less than 0.05). At 12 to 16 months efficacy was again present. Comparisons for 3 month peak effect with 12 to 16 month long-term effect and subsequent final placebo period were, respectively: first end point, 10.5 +/- 1.3, 9.4 +/- 1.0 and 6.6 +/- 1.7 minutes; second end point, 11.0 +/- 1.3, 10.2 +/- 1.2 and 6.3 +/- 0.7 minutes; and third end point, 12.1 +/- 1.0, 11.0 +/- 1.0 and 9.2 +/- 1.5 minutes. No significant adverse effects of hematologic abnormalities were noted.

Aged↗

The treatment of exercise-inducible chronic stable angina with diltiazem. Effect on treadmill exercise.

Although diltiazem has been shown to alleviate vasospastic angina pectoris, its effect on exercise-inducible chronic stable angina has not been objectively studied. Accordingly, the effect of diltiazem was studied in this condition with a placebo controlled double-blind randomized cross-over protocol at three dose levels (120, 180 and 240 mg/day) during graded treadmill exercise. Three end-points were evaluated: 1) time to onset of angina or fatigue if angina were eliminated; 2) time to 1 mm ST segment depression or fatigue if ST depression were eliminated; and 3) time to termination of exercise (2+ angina or fatigue). All end-points were prolonged at all dose levels. At the highest dose of 240 mg/day, time to onset angina or termination was prolonged from a placebo time of 8.0 +/ 0.9 to 9.8 +/- 0.9 minutes (p = < .001); time to ST depression or termination was prolonged from 7.8 +/- 0.9 to 9.1 +/- 0.8 minutes (p = .007); and time to termination was prolonged from 9.9 +/- 0.9 to 10.8 +/- 0.8 minutes (p = .02).

Aged↗

Augmented right ventricular function in systemic hypertension-induced hypertrophy.

The contractile properties of right ventricular papillary muscles from the hearts of 15 rats which had developed hypertension 6 weeks following renal artery ligation were compared with those from 14 normal litter-mates. In the experimental group, the heart weight-body weight ratio was increased by 39%, while the right ventricular weight-body weight ratio increased 20%. Right ventricular papillary muscles from the hypertensive rats demonstrated increased tension development at the apex of the length-active tension curve (P less than 0 X 0001), elevated maximal rate of tension development (P less than 0 X 001), and increased maximal velocity of contraction at muscle lengths corresponding to both a light preload and at Lmax (P less than 0 X 05). Resting tension and time-to-peak tension in the muscles from the hypertensive group were not significantly different from the normal group. Thus, improved right ventricular performance, in the presence of increased left ventricular afterload, may indicate the existence of a stimulus to increased function in hypertrophied muscle not yet negated by the adverse effects of direct exposure to stress.

Animals↗

Influence of hyperthyroidism on glycerol-extracted cardiac muscle from rabbits.

The mechanism responsible for the enhancement of myocardial contractility in hyperthyroidism is unclear. The possibility that this mechanism may involve a direct effect on the contractile proteins was investigated using the glycerol-extracted muscle strip from right ventricular papillary muscles of euthyroid rabbits and rabbits made hyperthyroid by the intraperitoneal injection of 0.25 mg/kg 1-thyroxine for 10 d. Intact papillary muscles from the hyperthyroid rabbits had an enhanced rate of tension development, a decreased time to peak tension, and a slight though insignificant increase in active tension compared to control animals. Maximal isometric contractions were induced in glycerol-extracted cardiac muscle strips from the two animal groups by the addition of 5 mmol/litre ATP and 5 mmol/litre MgCl in a buffer solution containing 0.15 mol/litre Tris-HCl (pH 7.1) at 26 degrees C. Peak isometric tension was increased in glycerinated muscle strips from hyperthyroid rabbits (1.52+/-0.10 vs 1.26 +/-0.13g/mm2), but the differences did not reach statistical significance. However, there was a marked increase in the rate of tension development in the hyperthyroid group (62.5+/-5.4 vs 41.8+/-4.7 mg/mm-2/s, P less than 0.01). This increase in the rate of isometric tension development in both intact and glycerinated muscles from hyperthyroid rabbits may be related to changes in the intrinsic turnover of actomyosin cross-bridge links in this condition. Thus, these findings suggest that thyroid hormone may influence cardiac muscle function by a direct effect on the contractile proteins.

Adenosine Triphosphate↗

Mechanochemistry of cardiac muscle. V. Influence of thyroid state on energy utilization.

The possibility that alterations in the rate or efficiency of energy utilization could be involved in the control of cellular oxygen consumption by thyroid hormone was examined in right ventricular papillary muscles isolated from normal euthyroid cats and cats with experimentally induced hyperthyroidism and hypothyroidism. Energy production in the muscles was inhibited and isolated from the process of energy utilization by exposure to iodoacetic acid and nitrogen. After resting or performing variable amounts of contractile element work under isometric conditions, muscles were frozen, and the total amount of chemical energy ( approximately P = creatine phosphate + ATP) used was determined. The resting rate of energy utilization in muscles from euthyroid animals was 0.78+/-0.07 mumoles/g per min of approximately P. This rate was elevated in muscles from hyperthyroid cats to 1.00+/-0.09 mumoles/g per min and decreased in muscles from hypothyroid cats to 0.23+/-0.14 mumoles/g per min. Isometrically contracting muscles from cats with hypothyroidism utilized only 64% as much energy as muscles from euthyroid cats while performing 81% as much contractile element work at a moderately decreased level of contractile state. Muscles from hyperthyroid cats utilized an average of 41% more energy than did muscles from euthyroid cats while contracting an identical number of times and performing an equal amount of contractile element work at a slightly increased level of contractile state. These results suggest that thyroid hormone directly influences the rate of cellular energy utilization. Furthermore, the increase in energy utilization in muscles from hyperthyroid cats could not be attributed entirely to observed alterations in contractile behavior, which indicates that excess thyroid hormone may decrease the efficiency of the conversion of cellular energy to work. However, the opposite effect, an increased efficiency of energy utilization, was not observed in muscles from hypothyroid cats. Thus, it is concluded that the calorigenic effects of thyroid hormone may be explained, at least in part, by alterations in the process of energy utilization.

Adenosine Triphosphate↗